Key facts
- It has raised $30.0M; the latest was Later Stage VC in Aug 2025.
- Notable investors include Green Pine Capital Partners, Cherami Investment Group, Shenyin & Wanguo Investment, Jingjie Investment, Star River Group — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for MindRank
- ·The full record, as it builds
Funding rounds
No funding rounds for MindRank are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MindRank
Developer of an artificial intelligence (AI)--empowered drug discovery company intended to accelerate the drug discovery process and deliver small molecule medicines with differentiation and clinical benefits. The company leverages its proprietary AI platforms, which quickly recommend low-cost and high-synthesis routes based on a given compound, and it also develops a drug design platform Molecule Pro, providing clients with effective drugs.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2020
- Website
- mindrank.ai/
- Ownership
- Privately Held (backing)
MindRank doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MindRank shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MindRank in its N-PORT filings yet. We sweep new filings monthly.